Review Highlights Emerging Engineering Strategies Including Combination Approaches Designed to Enhance Anti-Tumor Activity, Gamma-Delta T cell Engagers, CAR-Gamma-Delta T Cells and Cytokine-Armored Cells NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) — IN8bio, Inc. (NASDAQ: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers (TCEs) for cancer and autoimmune diseases, today announced the publication of a review article titled: “Harnessing γδ T cells through engineering and combination therapies” in the journal Nature Communications. IN8bio Chief Scientific Officer (CSO) Lawrence Lamb, Ph.D. was a contributing author to the review, which highlights advances in γδ T cell engineering, combination approaches, and clinical development strategies designed to improve anti-tumor...

WILMINGTON, Del., June 03, 2026 (GLOBE NEWSWIRE) — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals” or the “Company”), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering (the “Offering”) of 5,714,286 shares of its common stock, par value $0.001 per share (“Common Stock”) at a public offering price of $3.50 per share of Common Stock. The Company has also granted the underwriters a 30-day option to purchase up to an additional 857,142 shares of Common Stock. The gross proceeds of the Offering will be approximately $20.0 million (or $23.0 million if the underwriter exercises its option to purchase additional shares of Common Stock in full) before deducting underwriting discounts and commissions in the Offering and other estimated expenses payable by the Company....

Independent, Peer-Reviewed Study Demonstrated Significant Improvement in Patient Outcomes, Reduction in Over 350 Nursing Hours in Year One, and 20% Decrease in Repeat Imaging Validates Value of Integrating ENvue Navigation Platform as Standard of Care in U.S. Hospitals, Saving Costs on Nursing Hours, Imaging, and Patient Complications Findings Published in Official Journal of the American Association of Critical Care Nurses TYLER, Texas, June 03, 2026 (GLOBE NEWSWIRE) — ENvue Medical (NASDAQ: FEED) (“ENvue” or the “Company”), a commercial-stage medical device company focused on real-time guided bedside feeding tube placement, today announced that an independent, peer-reviewed study has been published in Critical Care Nurse – the official journal of the American Association of Critical Care Nurses – showing dramatic improvements...

Gabriella SahlmanCo-founder, Managing Partner Fuels CapitalRobin Gerum, Gabriella SahlmanRobin Gerum, CEO and co-founder Fuels Capital Gabriella Sahlman, Managing partner, co-founder Fuels CapitalSwedish private credit company raises maximum loan size to €25M,expanding asset-backed funding against all asset classes forentrepreneurs excluded from traditional finance Ex-Proventus Capital Partners co-founder Gabriella Sahlman joins asco-founder and Managing Partner after Fuels Capital achieved €8M ARRover the past yearSTOCKHOLM, SWEDEN. 3 JUNE 2026: Fuels Capital, a European private credit company,today extends its asset-backed loans of up to €25 million to entrepreneurs andcompany builders across Europe. This launch of Fuels Capital, a distinct business unit within financial services venture builder and investor...